The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter

European Journal of Pharmacology

Volumn 755, Issue , 2015, Pages 119-126

  Pifl, Christian ^a   Reither, Harald ^a   Hornykiewicz, Oleh ^a  

^a Medical University of Vienna   (Austria)

Author keywords

Amphetamines; Dopamine transporter; Noradrenaline transporter; Serotonin transporter; Synaptic vesicles; Vesicular monoamine transporter

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; DESIPRAMINE; DOPAMINE; DOPAMINE TRANSPORTER; FLUOXETINE; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; TRITIUM; VANOXERINE; VESICULAR MONOAMINE TRANSPORTER; METHAMPHETAMINE; SLC18A2 PROTEIN, HUMAN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IC50; INHIBITION KINETICS; NEUROBLASTOMA CELL LINE; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; SH SY5Y CELL LINE; STABLE EXPRESSION; SYNAPSE VESICLE; ANALOGS AND DERIVATIVES; HEK293 CELL LINE; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HEK293 CELLS; HUMANS; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTIC VESICLES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84925436690     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.03.004     Document Type: Article

References (37)

1. M. Angoa-Perez, M.J. Kane, D.M. Francescutti, K.E. Sykes, M.M. Shah, A.M. Mohammed, D.M. Thomas, and D.M. Kuhn Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum J. Neurochem. 120 2011 1097 1107
2. M.H. Baumann, M.A. Ayestas Jr., J.S. Partilla, J.R. Sink, A.T. Shulgin, P.F. Daley, S.D. Brandt, R.B. Rothman, A.E. Ruoho, and N.V. Cozzi The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue Neuropsychopharmacology 37 2012 1192 1203
3. M.H. Baumann, J.S. Partilla, and K.R. Lehner Psychoactive bath salts: not so soothing Eur. J. Pharmacol. 698 2013 1 5
4. M. Bayer, Z. Kuci, E. Schomig, D. Grundemann, H. Dittmann, R. Handgretinger, and G. Bruchelt Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells Nucl. Med. Biol. 36 2009 287 294
5. I.L. Bogen, K.H. Haug, O. Myhre, and F. Fonnum Short- and long-term effects of MDMA (ecstasy) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo Neurochem. Int. 43 2003 393 400
6. R.C. Callaghan, J.K. Cunningham, J. Sykes, and S.J. Kish Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs Drug Alcohol Depend. 120 2012 35 40
7. N.V. Cozzi, M.K. Sievert, A.T. Shulgin, P. Jacob III, and A.E. Ruoho Inhibition of plasma membrane monoamine transporters by beta- ketoamphetamines Eur. J. Pharmacol. 381 1999 63 69
8. J.F. Cubells, S. Rayport, G. Rajendran, and D. Sulzer Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress J. Neurosci. 14 1994 2260 2271
9. D.P. Daberkow, H.D. Brown, K.D. Bunner, S.A. Kraniotis, M.A. Doellman, M.E. Ragozzino, P.A. Garris, and M.F. Roitman Amphetamine paradoxically augments exocytotic dopamine release and phasic dopamine signals J. Neurosci. 33 2013 452 463
10. A.R. Green, M.V. King, S.E. Shortall, and K.C. Fone The preclinical pharmacology of mephedrone; not just MDMA by another name Br. J. Pharmacol. 171 2014 2251 2268
11. B. den Hollander, S. Rozov, A.M. Linden, M. Uusi-Oukari, I. Ojanpera, and E.R. Korpi Long-term cognitive and neurochemical effects of bath salt designer drugs methylone and mephedrone Pharmacol. Biochem. Behav. 103 2013 501 509
12. A.J. Eshleman, K.M. Wolfrum, M.G. Hatfield, R.A. Johnson, K.V. Murphy, and A. Janowsky Substituted methcathinones differ in transporter and receptor interactions Biochem. Pharmacol. 85 2013 1803 1815
13. T. Fujita, T.J. Urban, M.K. Leabman, K. Fujita, and K.M. Giacomini Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants J. Pharm. Sci. 95 2006 25 36
14. A.R. Green, A.O. Mechan, J.M. Elliott, E. O'Shea, and M.I. Colado The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") Pharmacol. Rev. 55 2003 463 508
15. D. Grundemann, G. Liebich, N. Kiefer, S. Koster, and E. Schomig Selective substrates for non-neuronal monoamine transporters Mol. Pharmacol. 56 1999 1 10
16. G.C. Hadlock, K.M. Webb, L.M. McFadden, P.W. Chu, J.D. Ellis, S.C. Allen, D.M. Andrenyak, P.L. Vieira-Brock, C.L. German, K.M. Conrad, A.J. Hoonakker, J.W. Gibb, D.G. Wilkins, G.R. Hanson, and A.E. Fleckenstein 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse J. Pharmacol. Exp. Ther. 339 2011 530 536
17. J.P. Hansen, E.L. Riddle, V. Sandoval, J.M. Brown, J.W. Gibb, G.R. Hanson, and A.E. Fleckenstein Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity J. Pharmacol. Exp. Ther. 300 2002 1093 1100
18. C.M. Hysek, A.E. Fink, L.D. Simmler, M. Donzelli, E. Grouzmann, and M.E. Liechti alpha(1)-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans J. Clin. Psychopharmacol. 33 2013 658 666
19. C.M. Hysek, L.D. Simmler, M. Ineichen, E. Grouzmann, M.C. Hoener, R. Brenneisen, J. Huwyler, and M.E. Liechti The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (ecstasy) in humans Clin. Pharmacol. Ther. 90 2011 246 255
20. L. Iversen, S. Gibbons, R. Treble, V. Setola, X.P. Huang, and B.L. Roth Neurochemical profiles of some novel psychoactive substances Eur. J. Pharmacol. 700 2013 147 151
21. E.A. Johnson, J.P. O'Callaghan, and D.B. Miller Chronic treatment with supraphysiological levels of corticosterone enhances D-MDMA-induced dopaminergic neurotoxicity in the C57BL/6J female mouse Brain Res. 933 2002 130 138
22. J. Kehr, F. Ichinose, S. Yoshitake, M. Goiny, T. Sievertsson, F. Nyberg, and T. Yoshitake Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats Br. J. Pharmacol. 164 2011 1949 1958
23. D. Kristufek, W. Rudorfer, C. Pifl, and S. Huck Organic cation transporter mRNA and function in the rat superior cervical ganglion J. Physiol. 543 2002 117 134
24. R. López-Arnau, J. Martinez-Clemente, D. Pubill, E. Escubedo, and J. Camarasa Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone Br. J. Pharmacol. 167 2012 407 420
25. D.B. Miller, and J.P. O'Callaghan The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine Mol. Neurobiol. 11 1995 177 192
26. C.P. Motbey, E. Karanges, K.M. Li, S. Wilkinson, A.R. Winstock, J. Ramsay, C. Hicks, M.D. Kendig, N. Wyatt, P.D. Callaghan, and I.S. McGregor Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion PLoS One 7 2012 e45473
27. N.P. Murphy, S.G. Ball, and P.F. Vaughan Potassium- and carbachol-evoked release of [3H]noradrenaline from human neuroblastoma cells, SH-SY5Y J. Neurochem. 56 1991 1810 1815
28. C. Pifl, H. Drobny, H. Reither, O. Hornykiewicz, and E.A. Singer Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter Mol. Pharmacol. 47 1995 368 373
29. C. Pifl, O. Hornykiewicz, B. Giros, and M.G. Caron Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter J. Pharmacol. Exp. Ther. 277 1996 1437 1443
30. C. Pifl, A. Rajput, H. Reither, J. Blesa, C. Cavada, J.A. Obeso, A.H. Rajput, and O. Hornykiewicz Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum J. Neurosci. 34 2014 8210 8218
31. R.B. Rothman, M.H. Baumann, C.M. Dersch, D.V. Romero, K.C. Rice, F.I. Carroll, and J.S. Partilla Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 39 2001 32 41
32. K.T. Schmidt, and D. Weinshenker Adrenaline rush: the role of adrenergic receptors in stimulant-induced behaviors Mol. Pharmacol. 85 2014 640 650
33. P. Scholze, J. Zwach, A. Kattinger, C. Pifl, E.A. Singer, and H.H. Sitte Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter J. Pharmacol. Exp. Ther. 293 2000 870 878
34. S.E. Shortall, A.E. Macerola, R.T. Swaby, R. Jayson, C. Korsah, K.E. Pillidge, P.M. Wigmore, F.J. Ebling, G.A. Richard, K.C. Fone, and M.V. King Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat Eur. Neuropsychopharmacol. 23 2012 1085 1095
35. L. Simmler, T. Buser, M. Donzelli, Y. Schramm, L.H. Dieu, J. Huwyler, S. Chaboz, M.C. Hoener, and M.E. Liechti Pharmacological characterization of designer cathinones in vitro Br. J. Pharmacol. 168 2013 458 470
36. T. Steinkellner, M. Freissmuth, H.H. Sitte, and T. Montgomery The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine Biol. Chem. 392 2011 103 115
37. M. Watabe, and T. Nakaki Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells Mol. Pharmacol. 74 2008 933 940